ArticleCancer2016

A phase 1 study of buparlisib and bevacizumab in patients with metastatic renal cell carcinoma progressing on vascular endothelial growth factor-targeted therapies.

Rana R McKay et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.